HCW Biologics Inc.
HCWB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.31 | -1.00 | -10.74 | -2.17 |
| FCF Yield | -2.09% | -1.62% | -0.75% | -0.33% |
| EV / EBITDA | -25.33 | -75.09 | -194.06 | -268.50 |
| Quality | ||||
| ROIC | -425.86% | -130.11% | -34.39% | -26.11% |
| Gross Margin | 37.38% | 19.72% | 38.48% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.90 | 0.70 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.45% | – | 17.92% | -100.00% |
| Free Cash Flow Growth | 49.54% | -38.99% | -87.44% | -3.81% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.11 | 1.13 | 0.95 |
| Interest Coverage | -25.45 | -90.86 | -119.05 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.96 | 0.00 |
| Cash Conversion Cycle | -4,988.34 | -789.42 | 37.57 | -150.18 |